Microbiome: Can Human Microbes Become A Panacea?

by Irina Bilous Contributor

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   1107    Comments 0
Topics: Industry Trends    Startups   

The microbiome is implicated in a number of metabolic pathways and communicates closely with our body in health and diseases. Imbalance of microflora is linked to obesity, diabetes, allergies, cancer, and even depression and autism. However, these facts have been ignored for decades. But today, the microbiome market is catching up, attracting considerable investments. The Wall Street Journal reported in 2018 that “from 2011 through 2015, venture funding in microbiome firms soared 458.5 percent to $114.5 million, while overall venture investment grew 103.4 percent to $75.29 billion. 

Recently, a Novartis-backed fund Seventure Partners announced it held the first close of its second microbiome fund now being more than halfway to its €200 million ($227 million)-plus fundraising target. This will set up Seventure to invest in around 20 European biotech startups focusing on microbiome drugs and diagnostics.

The microbiome startups are varied in their approach of creating therapies. Some companies are developing fecal transplants which are delivered from feces of healthy donors. This type of therapy can treat the recurrent C. difficile infection that is reversible in many cases and kills 12,800 in a year only in the USA. The Rebiotix (acquired by Ferring Pharmaceuticals in 2018) is one of the most successful companies that shipped fecal transplants against this disease. Their clinical candidate RBX2660 is in Phase 3 clinical development.  However it is needed to be careful with microbiota transplantation as several deaths have been reported recently caused by the pathogenic bacteria that donor’s stools contained.

Other companies are working on more precise therapies. Whole Biome, which recently raised $35 million in Series B funding, developed food medicine for diabetes type 2. Patients with this type of diabetes lack bacteria that  metabolize dietary fibers into short-chain fatty acids, which helps to control blood level of sugar. Whole Biome selected beneficial bacteria by comparing microbiota of healthy individuals and those with disorders. Vedanta Bioscience, a company developed immune-modulated therapies, raised more - $45.5 Million. The company has a large collection of pure bacteria strains and selects the most effective bacteria strains to stimulate CD8 T-cells to kill cancer cells, treat  food allergy and C. difficile infection. Another microbiome company, Finch Therapeutics, applies machine learning to identify the key microbes driving patient outcomes.  Seres Therapeutics partnered with AstraZeneca to define microbes that boost response on checkpoint immunotherapy, based on their previous suggestion.

BiopharmaTrend Premium

This content is available to our premium users.

Get the following benefits by becoming premium member:

  • - unlock premium articles
  • - get access to our industry reports
  • - support our independent media

 Join Now 

Already a member?

Topics: Industry Trends    Startups   

Share this:              

You may also be interested to read:



There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *